OncoCyte says clinical validation study for its DetermaVu™ lung cancer diagnostic won’t be completed until 2018, due to a consumables issue.
The engineered killer T cells are 1,000 times more sensitive to cancer cell antigens to allow much better targeting to cancer cell lines
In this webinar, multiplexing quantitative proteomics for profiling breast cancer patient-derived xenografts will be discussed.
Martin Tolar, Founder
President & CEO, Alzheon